ecancermedicalscience

Case Report

Cryptococcal meningoencephalitis in patients with mantle cell lymphoma on ibrutinib

17 May 2018
Kai Sun, Saro Kasparian, Swaminathan Iyer, Sai Ravi Pingali

Ibrutinib, a Bruton’s tyrosine kinase inhibitor, has been increasingly widely used in relapsed and refractory mantle cell lymphoma (MCL) and chronic lymphocytic leukaemia [1, 2]. With its use becoming more common, there have been emerging case reports of opportunistic infections like cryptococcal infections [3–8]. These infections in patients receiving ibrutinib were mostly reported in patients with chronic lymphocytic leukaemia, who have poor immune reconstitution. Here, we report two cases of cryptococcal meningoencephalitis in patients with MCL on ibrutinib.

Related Articles

Soumitra Shankar Datta, Sanjit Agrawal, Prateek Jain, Jeevan Kumar, Arnab Bhattacharjee, Ayush Bansal, Shagun Mahajan, Dibakar Podder, Kapila Manikantan, Gaurav Kumar, Bidisha Samanta, Sohini Sarkar, Soumita Ghose, Niladri Ghosal, Mary Guevera, Danny Burke
Susanna Hilda Hutajulu, Siswi Oktariani, Agus Jati Sunggoro, Bagas Suryo Bintoro, Yufi Kartika Astari, Juan Adrian Wiranata, Irianiwati Widodo, Anita Ekowati, Mardiah Suci Hardianti, Kartika Widayati Taroeno-Hariadi, Johan Kurnianda, Ibnu Purwanto
Glenn M Afungchwi, Elianeth Kiteni, Mariam Ndagire, Biemba Maliti, Rachael Kunkel, Julia M Challinor, Rachel Hollis
Elily Dianet Apumayta Requena, Danery Valdez Ocrospoma, Jhonatanael Salvador Ruiz, Alberto De la Guerra Pancorvo, Edgar Amorin Kajatt
Manju Sengar, Wilma M Hopman, Ghulam Rehman Mohyuddin, Aaron M Goodman, Bishal Gyawali, Deborah Mukherji, Nazik Hammad, CS Pramesh, Ajay Aggarwal, Richard Sullivan, Christopher M Booth